ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2006
CAMBRIDGE, Mass., Feb 07, 2006 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the BIO CEO & Investor Conference 2006 will be webcast live. The 25-minute presentation is scheduled to begin at 11:30 a.m. on February 14, 2006, and will be given at the Waldorf Astoria hotel in New York City. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until February 21, 2006.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent, cell-killing agent specifically to cancer cells. Three TAP compounds are in clinical testing - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and AVE9633, which is in development by the sanofi-aventis Group. A fourth TAP compound, trastuzumab-DM1 in development by Genentech, now has an effective IND. Genentech, Centocor (a wholly-owned subsidiary of Johnson & Johnson), Biogen Idec, the sanofi-aventis Group, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim, and Abgenix have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group.
SOURCE: ImmunoGen, Inc.
Investors:
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
info@immunogen.com
